Answers are grounded in this paper and cite their sources.
Quantitative systems pharmacology (QSP) models support model-informed drug development but are computationally expensive, limiting workflows requiring many simulations. Artificial intelligence (AI)-enabled surrogates can accelerate these workflows, but require validation aligned with context of use and regulatory expectations. Here, we present an eight-step validation framework covering simulation-campaign design, baseline comparison, endpoint accuracy, trajectory fidelity, uncertainty calibration, distributional agreement, biological plausibility, and computational efficiency. The framework is illustrated through chimeric antigen receptor T cell (CAR-T) immunotherapy and hybrid neural ordinary differential equation (ODE) erythropoiesis examples and aligned with ICH M15 and ASME V&V40. Supplementary algorithms provide practical validation recipes.
No takes yet. Share an insight, caveat, or question.
Goryanin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: